Literature DB >> 3412588

The risk of unprovoked seizures after encephalitis and meningitis.

J F Annegers1, W A Hauser, E Beghi, A Nicolosi, L T Kurland.   

Abstract

A population-based cohort of 714 survivors of encephalitis or meningitis between 1935 and 1981 was followed in order to evaluate the risks of unprovoked seizures after CNS infections. The 20-year risk of developing unprovoked seizures was 6.8%, and the ratio of observed to expected cases of unprovoked seizures was 6.9. The increased incidence of unprovoked seizures was highest during the first 5 years after the CNS infection but remained elevated over the next 15 years of follow-up. The type of CNS infection and the presence or absence of seizures during the acute phase of the CNS infection greatly influenced the risks of subsequent unprovoked seizures. The 20-year risk of developing unprovoked seizures was 22% for patients with viral encephalitis and early seizures, 10% for patients with viral encephalitis without early seizures, 13% for patients with bacterial meningitis and early seizures, and 2.4% for patients with bacterial meningitis without early seizures. The 20-year risk of 2.1% for patients with aseptic meningitis was not increased over the general population incidence of unprovoked seizures.

Entities:  

Mesh:

Year:  1988        PMID: 3412588     DOI: 10.1212/wnl.38.9.1407

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  43 in total

Review 1.  Infections, inflammation and epilepsy.

Authors:  Annamaria Vezzani; Robert S Fujinami; H Steve White; Pierre-Marie Preux; Ingmar Blümcke; Josemir W Sander; Wolfgang Löscher
Journal:  Acta Neuropathol       Date:  2015-09-30       Impact factor: 17.088

2.  Decrease in CA3 inhibitory network activity during Theiler's virus encephalitis.

Authors:  R M Smeal; R Fujinami; H S White; K S Wilcox
Journal:  Neurosci Lett       Date:  2015-10-23       Impact factor: 3.046

3.  Innate but not adaptive immune responses contribute to behavioral seizures following viral infection.

Authors:  Nikki J Kirkman; Jane E Libbey; Karen S Wilcox; H Steve White; Robert S Fujinami
Journal:  Epilepsia       Date:  2009-10-20       Impact factor: 5.864

Review 4.  Disease modification in epilepsy: from animal models to clinical applications.

Authors:  Melissa L Barker-Haliski; Dan Friedman; Jacqueline A French; H Steve White
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

5.  Indoleamine 2,3-dioxygenase 1 deletion promotes Theiler's virus-induced seizures in C57BL/6J mice.

Authors:  Michal B Juda; Alexandra K Brooks; Albert E Towers; Gregory G Freund; Robert H McCusker; Andrew J Steelman
Journal:  Epilepsia       Date:  2019-02-15       Impact factor: 5.864

6.  Acute treatment with minocycline, but not valproic acid, improves long-term behavioral outcomes in the Theiler's virus model of temporal lobe epilepsy.

Authors:  Melissa L Barker-Haliski; Taylor D Heck; E Jill Dahle; Fabiola Vanegas; Timothy H Pruess; Karen S Wilcox; H Steve White
Journal:  Epilepsia       Date:  2016-10-14       Impact factor: 5.864

Review 7.  Acute Symptomatic Seizures and Provoked Seizures: to Treat or Not to Treat?

Authors:  Nisali Gunawardane; Madeline Fields
Journal:  Curr Treat Options Neurol       Date:  2018-08-23       Impact factor: 3.598

Review 8.  Epidemiology of epilepsy in developing countries.

Authors:  N Senanayake; G C Román
Journal:  Bull World Health Organ       Date:  1993       Impact factor: 9.408

9.  Presynaptic L-Type Ca2+ Channels Increase Glutamate Release Probability and Excitatory Strength in the Hippocampus during Chronic Neuroinflammation.

Authors:  Giorgia Giansante; Antonella Marte; Alessandra Romei; Cosimo Prestigio; Franco Onofri; Fabio Benfenati; Pietro Baldelli; Pierluigi Valente
Journal:  J Neurosci       Date:  2020-08-03       Impact factor: 6.167

Review 10.  Treatment strategies after a single seizure : rationale for immediate versus deferred treatment.

Authors:  Laura C Miller; Frank W Drislane
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.